3D Medicines Inc. announced that on October 28, 2023, first commercial drug (Envafolimab) has received an approval from the U.S. Food and Drug Administration (the "FDA") to proceed with phase III Multinational, Multicenter, Randomized, Open label, Clinical Study Comparing Envafolimab plus Lenvatinib Versus Carboplatin paclitaxel as First Line Therapy in Subjects with Mismatch Repair Proficient (pMMR) Advanced or Recurrent Endometrial Cancer. The approval marks significant progress in global development.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 HKD | -1.10% | -5.97% | -17.54% |
03-29 | 3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12% | MT |
03-28 | 3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-17.54% | 200M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+1.63% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- 1244 Stock
- News 3D Medicines Inc.
- 3D Medicines Inc. Receives Approval from Fda to Proceed with Aglobal Phase Iii Trial for Treatment of the First Line Mismatch Repair ProficientAdvanced or Recurrent Endometrial Cancer